Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics Inc (CKPT)
NASDAQ:CKPT
CKPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $4.50
Previous CloseN/A
Volume626.20K
Average Volume (3M)3.94M
Market Cap
$198.75M
Enterprise Value$91.96M
Total Cash (Recent Filing)$4.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
May 08, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding48,132,500
10 Day Avg. Volume10,478,574
30 Day Avg. Volume3,943,082
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4228.69
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit892.79
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$5.30Price Target Upside30.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Checkpoint Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
AcquisitionCheckpoint is being acquired by Sun Pharmaceuticals at a significant premium, representing a major achievement for the company.
Drug ApprovalCheckpoint's drug, cosibelimab-ipdl, received FDA approval as the first and only PD-L1 blocking antibody for certain cSCC patients, marking a significant advancement.
Strategic PartnershipCheckpoint announced a collaboration with GC Cell to explore the combination of Checkpoint's cosibelimab with GC Cell's autologous cytokine-induced killer T cell therapy, Immuncell-LC, which could enhance therapeutic options and broaden the spectrum of treatable diseases.
Bears Say
Capital RequirementThere is less than a 5% likelihood that the company will raise the capital required to commercialize UNLOXCYT itself.
Financial PerformanceCheckpoint announced 3Q24 results, posting an EPS of ($0.23) compared to the consensus estimate of ($0.15).
---
Ownership Overview
25.36% Insiders
4.69% Mutual Funds
11.34% Other Institutional Investors
54.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CKPT FAQ
What was Checkpoint Therapeutics Inc’s price range in the past 12 months?
Checkpoint Therapeutics Inc lowest stock price was $1.38 and its highest was $4.50 in the past 12 months.
What is Checkpoint Therapeutics Inc’s market cap?
Checkpoint Therapeutics Inc’s market cap is $198.75M.
When is Checkpoint Therapeutics Inc’s upcoming earnings report date?
Checkpoint Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 45 days.
How were Checkpoint Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Checkpoint Therapeutics Inc overvalued?
According to Wall Street analysts Checkpoint Therapeutics Inc’s price is currently Undervalued.
Does Checkpoint Therapeutics Inc pay dividends?
Checkpoint Therapeutics Inc does not currently pay dividends.
What is Checkpoint Therapeutics Inc’s EPS estimate?
Checkpoint Therapeutics Inc’s EPS estimate is -0.16.
How many shares outstanding does Checkpoint Therapeutics Inc have?
Checkpoint Therapeutics Inc has 48,132,500 shares outstanding.
What happened to Checkpoint Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Checkpoint Therapeutics Inc?
Currently, no hedge funds are holding shares in CKPT
---
Checkpoint Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.30 (30.22% Upside)
$5.30 (30.22% Upside)
Insider Transactions
Sold Shares
Worth $336.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 13.3%
Last 30 Days ▼ 13.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.21%
12-Months-Change
Fundamentals
Return on Equity
369.09%
Trailing 12-Months
Asset Growth
133.50%
Trailing 12-Months
Company Description
Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.
---
CKPT Stock 12 Month Forecast
Average Price Target
$5.30
▲(30.22% Upside)
Technical Analysis
Best Analysts Covering CKPT
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+14.65%
reiterated a buy rating 15 days ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.65% per trade.
---